Alnylam Pharmaceuticals

Alnylam Pharmaceuticals: Convertible Note Funding Round

Alnylam Pharmaceuticals has successfully raised $360M in Convertible Note funding, reaching a valuation of $25B.

Company Overview

RNAi therapeutics

Funding Details

The Convertible Note round was led by Millennium Partners, with participation from Polaris Partners, Temasek Holdings.

Company Information

• Headquarters: 675 West Kendall Street, Cambridge, MA 02142
• Founded: 2002
• Employees: 2000+
• Category: Biotech

Investment

Alnylam Pharmaceuticals plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

• Millennium Partners: Verified investor in Convertible Note
• Polaris Partners: Verified investor in Convertible Note
• Temasek Holdings: Verified investor in Convertible Note